Author:
Filippini Graziella,Clerico Marinella,Beiki Omid,Mattoscio Miriam,Piazza Federico,Del Giovane Cinzia,Fredrikson Sten,Tramacere Irene,Scalfari Antonio
Reference88 articles.
1. Active Biotech Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP http://www.activebiotech.com/press-releases-1?pressurl=http://cws.huginonline.com/A/1002/PR/201401/1756936.xml.
2. Immunomodulation neuroprotection and remyelination. The fundamental therapeutic effects of glatiramer acetate: a critical review;Aharoni;Journal of Autoimmunity,2014
3. Biogen FDA accepts biologics license application for ZINBRYTA (Daclizumab High-Yield Process) for treatment of MS. Biogen, 29 Apr 2015 http://biogen.newshq.businesswire.com/press-release/corporate/fda-accepts-biologics-license-application-zinbryta-daclizumab-high-yield-pro
4. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists;Broadley;Journal of Clinical Neuroscience,2014
5. Graphical tools for network meta-analysis in Stata;Chaimani;PLoS One,2013
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献